| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Currently, metallo-β-lactamase(MBL)-producing Pseudomonas aeruginosa is the most intractable pathogen in many hospitals. The persistent biofilms formed by MBL-producing P. aeruginosa isolates, which may also be multiple-drug-resistant P. aeruginosa(MDRP), could cause serious problems in nosocomial infections. In this study period, we used newer methods for molecular epidemiological analyses and found valuable evidence for preventing nosocomial infections. In addition, we found promising therapeutic approaches for treating biofilm infections caused by MDRP using novel in vitro and in vivo models.
|
